1.Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M et al. Chemoradiotherapy of Locally Advanced Esophageal Cancer Long-term Follow-up of a Prospective Randomized Trial (RTOG 85–01). The Journal of the American Medical Association 281(17), 1623–1627 (1999).
2.Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Medical Oncology 29(5), 3017–3023 (2012).
3.Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma. Diseases of the Esophagus 23(3), 253–259 (2010).
4.Zhu Y, Zhang W, Li Q, Li Q, Qiu B, Liu H et al. A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma. Journal of Cancer 8(18), 3657–3666 (2017).
5.Yap JT, Carney JPJ, Hall NC, Townsend DW, Knoxville T. Image-guided cancer therapy using PET/CT. Journal of Cancer 10(4), 221–233 (2004).
6.Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A et al. PET/CT in cancer research: from preclinical to clinical applications. Contrast Media & Molecular Imaging 5(4), 190–200 (2010).
7.Hsu PP, Sabatini DM. Cancer Cell Metabolism: Warburg and Beyond. Cell 134(5), 703–707 (2008).
8.Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ et al. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. European Journal of Radiology 83(7), 1169–1176 (2014).
9.Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Annals of Oncology 24(1), 208–214 (2012).
10.Lin P, Min M, Lee M, Holloway L, Forstner D, Bray V et al. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers. European Journal of Nuclear Medicine and Molecular Imaging 44(5), 801–811 (2016).
11.Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG et al. Analysis of Pretreatment FDG-PET SUV Parameters in Head-and-Neck Cancer: Tumor SUVmean Has Superior Prognostic Value. International Journal of Radiation Oncology*Biology*Physics 82(2), 548–553 (2012).
12.Guler OC, Torun N, Yildirim BA, Onal C. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy. The British Journal of Radiology 91(1084), 20170552 (2018).
13.Hatt M, Van Stiphout R, Le Pogam A, Lammering G, Visvikis D, Lambin P. Early prediction of pathological response in locally advanced rectal cancer based on sequential18F-FDG PET. Acta Oncologica 52(3), 619–626 (2012).
14.Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 38(9), 1628–1635 (2011).
15.Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 454(7203), 436–444 (2008).
16.Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic Inflammation and Cytokines in the Tumor Microenvironment. Journal of Immunology Research 2014 1–19 (2014).
17.Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nature Reviews Cancer 13(11), 759–771 (2013).
18.Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI et al. Elevated Preoperative Neutrophil:Lymphocyte Ratio as a Predictor of Postoperative Disease Recurrence in Esophageal Cancer. Annals of Surgical Oncology 18(12), 3362–3369 (2011).
19.Sato H, Tsubosa Y, Kawano T. Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer. World Journal of Surgery 36(3), 617–622 (2012).
20.Yoo EJ, Park JC, Kim EH, Park CH, Shim CN, Lee HJ et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Digestive and Liver Disease 46(9), 846–853 (2014).
21.Liu X, Li M, Zhao F, Zhu Y, Luo Y, Kong L et al. The lymphocyte–monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy. OncoTargets and Therapy Volume 10 871–877 (2017).
22.Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, Mccarthy SW et al. Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. Journal of Clinical Oncology 30(21), 2678–2683 (2012).
23.Sa R. Progress in human tumour immunology and immunotherapy. Nature 17(411), 380–384 (2001).
24.Mcsorley ST, Khor BY, Tsang K, Colville D, Han S, Horgan PG et al. The relationship between 18F-FDG-PETCT-derived markers of tumour metabolism and systemic inflammation in patients with recurrent disease following surgery for colorectal cancer. Colorectal Disease 20(5), 407–415 (2018).
25.Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. British Journal of Cancer 108(4), 914–923 (2013).
26.Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, L Ress A et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. British Journal of Cancer 109(2), 416–421 (2013).
27.Prabawa IPY, Bharghah A, Liwang F, Tandio DA, Tandio AL, Lestari AaW et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pacific Journal of Cancer Prevention 20(3), 863–868 (2019).
28.Miyamoto R, Inagawa S, Sano N, Tadano S, Adachi S, Yamamoto M. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. European Journal of Surgical Oncology 44(5), 607–612 (2018).
29.Kosumi K, Baba Y, Ishimoto T, Harada K, Nakamura K, Ohuchi M et al. Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients. Surgery Today 46(4), 405–413 (2015).
30.Rashid F, Waraich N, Bhatti I, Saha S, Khan RN, Ahmed J et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World Journal of Surgical Oncology 8(1), (2010).
31.Dutta S, Fullarton GM, Mcmillan DC, Crumley ABC, Horgan PG. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World Journal of Surgery 35(8), 1861–1866 (2011).
32.Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S et al. Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer. Anticancer Research 38(8), 4927–4931 (2018).
33.Jeong E, Hyun SH, Moon SH, Cho YS, Kim B-T, Lee K-H. Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection. Medicine 96(5), e5935 (2017).
34.Du S, Sun H, Gao S, Xin J, Lu Z. Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational 18F-FDG PET/CT study. Quantitative Imaging in Medicine and Surgery 9(3), 440–452 (2019).
35.Xu J, Li Y, Hu S, Lu L, Gao Z, Yuan H. The significant value of predicting prognosis in patients with colorectal cancer using 18F-FDG PET metabolic parameters of primary tumors and hematological parameters. Annals of Nuclear Medicine 33(1), 32–38 (2018).
36.Sürücü E, Demir Y, Şengöz T. The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer. Annals of Nuclear Medicine 29(10), 906–910 (2015).
37.Mirili C, Guney IB, Paydas S, Seydaoglu G, Kapukaya TK, Ogul A et al. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET–CT metabolic parameters in small cell lung cancer (SCLC). International Journal of Clinical Oncology 24(2), 168–178 (2018).
38.Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine–18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. Journal of Nuclear Medicine 33(11), 1972–1980 (1992).
39.Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. Journal of Nuclear Medicine 36(9), 1625–1632 (1995).
40.Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune Consequences of Tyrosine Kinase Inhibitors that Synergize with Cancer Immunotherapy. Cancer Cell & Microenvironment 2(1), e677 (2015).
41.Seo S, Yoh T, Morino K, Fuji H, Taura K, Fukumitsu KEN et al. The Relationship Between 18F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma. Anticancer Research 39(1), 341–346 (2019).
42.Shi S, Ye L, Zhao Q, Hu Y, Huang Y, Chen G et al. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy. Japanese Journal of Clinical Oncology 49(4), 367–372 (2019).
43.St-Pierre Y, Choi Y, Oh D-Y, Park H, Kim T-Y, Lee K-H et al. More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. Plos One 11(1), e0145692 (2016).